Amgen’s Repatha gains an edge on rival Praluent with FDA approval to treat children with rare cholesterol condition
Though it has struggled to live up to early commercial expectations, Amgen’s cholesterol treatment Repatha has largely had the best of its rival in the market, Sanofi...
Continue Reading →
